Why the study?
What are the pharmacokinetic properties of esmolol in anesthetized patients undergoing coronary artery surgery on chronic beta blocker therapy?
Population
19 anesthetized patients undergoing coronary artery surgery who were receiving chronic beta blocker therapy
Design
Cohort
Follow-up
up to 40 min after discontinuation of the infusion
Authors
Loading...
Supports short-acting use in this surgical cohort; extends PK data in chronic beta-blocker users but leaves generalizability open.
What are the pharmacokinetic properties of esmolol in anesthetized patients undergoing coronary artery surgery on chronic beta blocker therapy?
Esmolol exhibits an ultra-short elimination half-life of approximately 10 minutes in patients undergoing coronary artery surgery.
Bruljn et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: